OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Results of Operations and Financial Condition

OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02 Results of Operations and Financial Condition.

On May3, 2017, OraSure Technologies, Inc. (the Company) issued a
press release announcing its consolidated financial results for
the quarter ended March31, 2017, and providing financial guidance
for the second quarter of 2017. A copy of the press release is
attached as Exhibit 99.1 to this Form 8-K and is incorporated
herein by reference.

The information in this Item and attached Exhibit shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that
section, nor shall such information and Exhibit be deemed
incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific
reference in such a filing. The fact that the information and
Exhibit are being furnished should not be deemed an admission as
to the materiality of any information contained therein. The
Company undertakes no duty or obligation to publicly update or
revise the information contained in this Current Report or
attached Exhibit.

Item7.01 Regulation FD Disclosure.

On May3, 2017, the Company held a webcast conference call with
analysts and investors, during which Douglas A. Michels, the
Companys President and Chief Executive Officer, and Ronald H.
Spair, the Companys Chief Financial Officer and Chief Operating
Officer, discussed the Companys consolidated financial results
for the quarter ended March31, 2017, provided financial guidance
for the second quarter of 2017 and described certain business
developments. A copy of the prepared remarks of Messrs. Michels
and Spair is attached as Exhibit 99.2 to this Form 8-K and is
incorporated herein by reference.

The information in this Item and attached Exhibit shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that
section, nor shall such information and Exhibit be deemed
incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific
reference in such a filing. The fact that the information and
Exhibit are being furnished should not be deemed an admission as
to the materiality of any information contained therein. The
Company undertakes no duty or obligation to publicly update or
revise the information contained in this Current Report or
attached Exhibit.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNumber

Description

99.1 Press Release, dated May3, 2017, announcing consolidated
financial results of OraSure Technologies, Inc. for the
quarter ended March31, 2017, and providing financial guidance
for the second quarter of 2017.
99.2 Prepared Remarks of Douglas A. Michels and Ronald H. Spair
for OraSure Technologies, Inc. First Quarter 2017 Analyst/
Investor Conference Call held May3, 2017.


About OraSure Technologies, Inc. (NASDAQ:OSUR)

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.

OraSure Technologies, Inc. (NASDAQ:OSUR) Recent Trading Information

OraSure Technologies, Inc. (NASDAQ:OSUR) closed its last trading session down -0.17 at 13.21 with 1,065,454 shares trading hands.

An ad to help with our costs